| Document |
Document Title |
|
WO/2023/230702A1 |
Screening for novel antibacterial compounds in small molecule libraries has a low success rate. Here, we applied a machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimenta...
|
|
WO/2023/232019A1 |
Provided are a 7-cyano-8-hydroxyquinoline derivative, a preparation method therefor and a medical use thereof. Specifically, disclosed are a compound represented by general formula (I), a preparation method therefor, a pharmaceutical com...
|
|
WO/2023/221123A1 |
Solid forms of an estrogen receptor (ER) inhibitor, compositions thereof and methods of treating an ER-mediated disorder are provided.
|
|
WO/2023/225563A2 |
The present disclosure relates to compounds that may be used to modulate the activity of a σ2R/TMEM97 receptor. The compounds may be further defined by the formula: (IA), (IB), or (IC) wherein the variables are as described herein. The ...
|
|
WO/2023/225586A2 |
Aspects of this invention are related to novel compounds of Formula I and compositions thereof that are inhibitors of glycogen synthase kinase 3 beta (GSK3β). Some aspects of the invention relate to novel compounds and compositions havi...
|
|
WO/2023/208865A1 |
There is disclosed a compound of Formula (II), a method of manufacturing thereof as well as uses thereof.
|
|
WO/2023/208867A1 |
There is disclosed a compound of Formula (I), a method of manufacturing thereof as well as uses thereof.
|
|
WO/2023/208869A1 |
There is disclosed a compound of Formula (III), a method for manufacturing thereof as well as uses thereof.
|
|
WO/2023/208151A1 |
The present disclosure provides a compound which has an inhibitory effect on USP, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, as shown in formula (I), the definition of each group in the formula be...
|
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
|
WO/2023/196454A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. ...
|
|
WO/2023/172649A9 |
The present invention relates to a drug approved for the treatment of hypomobility in patients with Parkinson's disease. The invention further relates to apomorphine hydrochloride trimethanolate (III), its polymorphs, pharmaceutical uses...
|
|
WO/2023/187677A1 |
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L6, n, R2, R3, R4, R5, R7, R8, R9, R10, R11, R12, R13, R14, R15 and X1 are defined in the specification. This disclosure also relates to materia...
|
|
WO/2023/187099A1 |
The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.
|
|
WO/2023/160302A9 |
A C19 diterpene alkaloid, a preparation method therefore and an application thereof, which relate to the technical field of medicines. The structure of the C19 diterpene alkaloid is shown in formula (I). Pharmacodynamic experiments show ...
|
|
WO/2023/178809A1 |
A synthesis method for nuciferine or a derivative thereof, a nuciferine derivative and an application thereof. A compound having a structure shown in formula IV and R-X undergo a Schotten-Baumann reaction, and then nuciferine having a st...
|
|
WO/2023/179205A1 |
Provided are a diimide derivative, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than th...
|
|
WO/2023/166531A1 |
The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitiv...
|
|
WO/2023/164889A1 |
Disclosed are a method for preparing codeine and a derivative and intermediate thereof. Simple, cheap and easily-available commercially available compounds are used as starting materials in the present invention, various intermediates th...
|
|
WO/2023/156565A1 |
Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds u...
|
|
WO/2023/158722A2 |
The present disclosure encompasses a process for chiral resolution of racemic amines, particularly ethyl 2-(4-((tert-butoxycarbonyl)amino)phenyl)piperidine-3-carboxy
late, into its desired isomer, ethyl (2R,3S)-2-(4-((tert-butoxycarbonyl...
|
|
WO/2023/154499A1 |
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
|
WO/2023/152346A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/142857A1 |
Disclosed in the present invention is a preparation method of Rimegepant. Specifically, the preparation method comprises the following steps: 1) reacting a compound of formula (III) with a compound of formula (IV) in a solvent 1, in the ...
|
|
WO/2023/138657A1 |
A quinoline amine compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to a quinoline amine compound represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2023/137962A1 |
Disclosed in the present invention is an oxidized isoaporphine alkaloid derivative having a structure as shown in formula I, wherein R1 and R2 are independently selected from H, F, Cl and methoxy, respectively; and n is an integer of 2-6...
|
|
WO/2023/126951A1 |
Disclosed herein are inhibitors of autophagy-related protein-protein interactions and their use for treating an autophagy-related disease or disorder, cancer, a cytokine release syndrome (CRS) or a cytokine storm in a subject.
|
|
WO/2023/112056A1 |
The present invention provides a compound formula (I), Formula (I) wherein, R1, R2, R3, R5, R6, R7, R8, R9, X, Z1 and Z2 are as defined in the detailed description and a process for preparing the compound of formula (I). The present inve...
|
|
WO/2023/105029A1 |
The present invention relates to terrylene diimides which are substituted in the skeleton and their homologous quaterrylene diimides. The present invention also relates to specific uses of these compounds, especially to their use in an i...
|
|
WO/2023/105008A1 |
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
|
|
WO/2023/102652A1 |
The present application provides compounds which are attachable to skin, in particular hydrogenated genipin compounds and de-glycosylated oleuropein compounds, which are useful, for example, as colorants and sunscreens.
|
|
WO/2023/101981A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
|
|
WO/2023/101256A1 |
The present invention is a novel compound and a composition including same for preventing hair loss and promoting hair growth, wherein the compound is able to inhibit only 5-alpha-reductase around the scalp and hair follicle, with the co...
|
|
WO/2023/085046A1 |
The present disclosure provides an organic compound characterized by being represented by general formula [1].
|
|
WO/2023/085432A1 |
The present invention pertains to: a compound represented by formula (I) [in the formula, R1 represents C1-C8 alkyl or the like, R2-R9 each independently represent hydrogen, a halogen, hydroxyl, NH2, Q-(C1-C8 alkyl) (Q represents O, NH, ...
|
|
WO/2023/083210A1 |
Disclosed is a substituted naphthyridinone derivative, which has a structure as shown in formula (I). Further provided are a pharmaceutically acceptable salt, stereoisomer and pharmaceutical composition of the derivative and the medicina...
|
|
WO/2023/085420A1 |
The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
|
|
WO/2023/078824A1 |
The present invention relates to compounds of the spiro-(indane- fluorene) type of formula (I), in particular those bearing a primary amino group and the corresponding diarylamino compounds. The invention further relates to methods for p...
|
|
WO/2023/077218A1 |
There is provided a process for alkylating a substrate with a photocatalytic system. The process comprises providing a mixture containing an acid, and a substrate (an organic compound). Then, an organophotoredox catalyst of formula Ia is...
|
|
WO/2023/060022A1 |
The present disclosure provides new methods of preparing a compound of Formula (I). Such methods can prepare the compound at any scale, including gram and kilogram scale.
|
|
WO/2023/054678A1 |
This organic EL element (1) comprises a light-emitting region (5) disposed between a negative electrode (4) and a positive electrode (3), a first positive-electrode-side organic layer (61), and a second positive-electrode-side organic la...
|
|
WO/2022/170974A9 |
Provided are a compound of formula (I) that inhibit the activity of PARP7, a stereoisomer thereof, a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, an intermediate to prepare the compound, a process to prep...
|
|
WO/2023/039662A1 |
The present disclosure provides compounds according to Formulas I and II: where R1 to R11 independently denote: H; D; a halogen; an optionally substituted straight chain or branched alkyl group; an optionally substituted alkenyl group; a...
|
|
WO/2023/041055A1 |
Disclosed is a class of KIF18A inhibitors. Specifically, the present invention relates to a compound as represented by general formula (1), a preparation method therefor, and the use of the compound as represented by general formula (1) ...
|
|
WO/2023/038876A1 |
The disclosure provides quinoline and quinazoline derivative compounds and pharmaceutical compositions thereof. These compounds inhibit the interactions between GAG- binding amyloid peptides (GBAPs) and heparan sulfate glycosaminoglycans...
|
|
WO/2023/033874A1 |
The present disclosure relates generally to multimeric dyes, colored dielectric polymer materials, methods of making them and uses thereof. In particular, the application concerns a colored dielectric polymer material comprising a multim...
|
|
WO/2023/284833A1 |
Provided are a spirocyclic piperidine derivative, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof, the derivative being as shown in formula (A). The derivative may be used as an MOP receptor, an NOP...
|
|
WO/2023/282236A1 |
This rare earth complex is represented by a general formula (1). (In the formula, HC is a quinolinonato ligand and cumalinato ligand; L1 is a nitrogen-containing ligand, etc.; L2 is water, etc.; XL is a halide ion, etc.; M3+ is a trivale...
|
|
WO/2022/268230A1 |
The present invention provides a compound as a KIF18A inhibitor. Specifically, the present invention provides a compound having a structure as represented by the following formula (I), or an optical isomer, pharmaceutically acceptable sa...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
